71 related articles for article (PubMed ID: 8311489)
1. [Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A].
Nomura Y; Abe O; Tominaga T; Tashiro H; Hisamatsu K; Enomoto K; Fujiwara K; Imoto S; Ando J; Hayashi K
Gan To Kagaku Ryoho; 1994 Feb; 21(2):189-97. PubMed ID: 8311489
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
[TBL] [Abstract][Full Text] [Related]
3. [Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
Wada T; Nomura Y; Oohashi Y; Abe O; Koyama H; Takashima S
Gan To Kagaku Ryoho; 1994 Mar; 21(4):485-93. PubMed ID: 8129389
[TBL] [Abstract][Full Text] [Related]
4. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
6. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial].
Aoyama H; Asaishi K; Abe R; Kajiwara T; Enomoto K; Yoshida M; Ohasi Y; Tominaga T; Abe O
Gan To Kagaku Ryoho; 1994 Mar; 21(4):477-84. PubMed ID: 8129388
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
9. [Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group].
Fukuda M; Watanabe H; Suda T; Shimizu S
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2201-8. PubMed ID: 10635305
[TBL] [Abstract][Full Text] [Related]
10. [Introduction of a new aromatase inhibitor fadrozole hydrochloride hydsate].
Tsukagoshi S
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1991-7. PubMed ID: 7487133
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
12. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
13. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
14. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
15. [A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen].
Tominaga T; Kimura M; Toge T; Takashima S; Nomura Y; Ohashi Y
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1709-18. PubMed ID: 11057322
[TBL] [Abstract][Full Text] [Related]
16. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
17. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors in metastatic breast cancer.
Buzdar AU; Plourde PV; Hortobagyi GN
Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells.
Yano S; Tanaka M; Nakao K
Eur J Pharmacol; 1995 Apr; 289(2):217-22. PubMed ID: 7621894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
